PTPA and brain neoplasm: The discovery of small-molecule antagonists of PP2A inhibitors, especially CIP2A and SET, has provided insight into the mechanisms of PP2A dysregulation in brain tumors, highlighting a therapeutic avenue with promising potential (Table 1) [25,29].